Sidley Represents Galera Therapeutics in Its Merger With Obsidian Therapeutics and US$350 Million Private Placement Financing

Sidley represented Galera Therapeutics, Inc. in its business combination with Obsidian Therapeutics, Inc., creating a combined company that will operate as Obsidian Therapeutics, Inc. The transaction was accompanied by a US$350 million concurrent private placement financing, which is expected to fund the combined company into the second half of 2028 and support the achievement of multiple anticipated clinical milestones in 2027.

More information about the transaction is available here.

The Sidley team was led by Asher Rubin (Technology and Life Sciences Transactions), John Butler (M&A), and Istvan Hajdu (Capital Markets), and included Alison Lehner (Emerging Companies and Venture Capital); Amanda Chong Artese (Technology and Life Sciences Transactions); Nikita Ponomarev, Emily Chazen, Brendan McCartney, and Suzanna Lewis (M&A); Sonia Gupta Barros, Katie Klaben, Kayla M. West, Kendell Lee, Demetrius Watson, and Tanvi Sharan (Capital Markets); Andrea Reed (Corporate Governance); Vadim Brusser (Antitrust and Competition), Torrey Cope and Kevin Sforza (Food, Drug and Medical Device); Christian Brause, Greg Featherman, Eric Grosshandler, and Morgan Ross (Tax); Benjamin Nager (Securities Enforcement and Regulatory); and Zani Doumbia (Investment Funds).